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Abstract
Introduction
The persistence of COVID-19 sequelae is very common 14 days after acute infection. The term “long-CO-
VID” has been proposed in order to refer to all the secondary conditions to SARS-CoV-2 infection which 
continue or appear after its acute stage. One of the sequelae is chronic pain with non-demonstrated organ 
involvement. This systematic review aims to identify the most commonly reported painful sequelae and 
their incidence.
Methods
A search for articles documenting pain as a consequence of COVID-19 was conducted. The consulted 
databases were PubMed/Medline, Scopus, and Web of Science. Certain articles cited in the references of 
relevant articles were also incorporated. Depending on the detailed inclusion or exclusion criteria, three 
independent researchers carried out the selection. All the articles published before March 11th 2021 were 
included. This systematic review is based on the PRISMA guidelines.
Results
A total of 588 publications were identified, of which 11 met the inclusion criteria. Headache was the most 
frequently reported painful sequela, with a prevalence of up to 44% in some cases. Joint pain (19%-31%) 
and post-COVID thoracic pain (6%-28%) were notified. Persistent sore throat was reported in 32% of 
patients, as well as generalized pain, observed in up to 59% of the cases. Patient’s polyneuropathy that 
required admission to the internal care unit (ICU) was additionally notified. SARS-CoV-2 causes damage 
at the capillary microcirculation level, generating tissue hypoxia and inflammation, with the consequent 
increase in painful vascular-ischemic and inflammatory sequelae.
Conclusions
COVID-19 produces painful sequelae of various typologies. Subsequent studies are required in order to 
identify the characteristics of every different type of pain. This will allow an adequate symptomatologic 
management and an optimization of the available resources to face the challenges of the current pandemic 
in different healthcare areas.
Keywords: COVID-19, SARS-CoV-2, coronavirus, pain, painful sequelae, long-COVID, post-COVID, per-
sistent COVID.
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1. Introduction
Since the first COVID-19 case reported in Wuhan 
(1) on December 31st 2019, 116 million people (2) 
have been infected as of March 21st 2021. Many of 
them do not fully recover but suffer long-term uns-
pecific chronic pain. These effects are not widely 
known yet (3). Cases of fatigue, headache, difficulty 
concentrating, hair loss and dyspnea (3, 12, 18) are 
reported with high frequency. For this reason, the 
term “long-COVID” has been suggested in order to 
bring together all the sequelae that arise two weeks 
after the disease has passed (4, 8).
It has been demonstrated that presence and severi-
ty of somatic symptoms during acute infection are 
closely related to the subsequent development of 
chronic fatigue and pain (11, 25). The daily clinical 
experience of the last few months in the Andalusian 
Health System (SAS, for its acronym in Spanish, Sis-
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tema Andaluz de Salud), has experienced an increa-
se of the influx in healthcare centers of patients with 
persistent COVID-19 symptoms. These symptoms 
worsen the quality of life, are difficult to identify in 
the diagnosis and do not disappear easily with the 
usual treatments (5). The most common symptoms 
are myalgia, referred pain, and generalized hyperal-
gesia (17). They appear in different locations: head 
(20) and in thorax or limbs (15). Moreover, this di-
sease responds to variable characteristics. Organicity 
has been ruled out, so the causal mechanism is unk-
nown. However, it is being studied, and it is only as-
sociated with convalescence after COVID-19 (8).
It is unknown whether COVID-19 will cause an in-
crease in new-onset chronic pain. The objective of 
this systematic review is to comprehensively com-
pile reported data on pain as COVID-19 sequela. 
The secondary objective is to analyze whether the 
incidence of post-COVID chronic pain during the 
pandemic has increased. It is of interest to evaluate 
in future studies the patterns of post-COVID chro-
nic pain, as well as its risk factors, intensity, charac-
teristics, and response to currently used treatment.
2. Methods
A systematic review of the literature was carried out 
by three independent researchers (VPF, PCP, and 
PJG). The consulted databases were PubMed, Sco-
pus and Web of Science. March 11th 2021 was the 
due date for article selection. In order to increase the 
sensitivity of the research, the bibliography cited in 
the articles finally selected was also reviewed. The 
followed strategy was based on the PRISMA gui-
delines (24). The search terms were “COVID-19”, 
“long*”, and “pain”, joined by the Boolean operator 
“AND”.
2.1. Search strategy and selection criteria
Publications available in English or Spanish were 
identified. Articles analyzing data from patients 
with pain symptoms more than two weeks after 
confirmed acute SARS-CoV-2 infection were se-
lected. Non-ambulatory and ambulatory patients 
which required internal care unit (ICU) admis-
sion were included. Only data on the adult popu-
lation were used. Prospective, retrospective and 
cross-sectional observational cohort studies were 
included, as well as systematic reviews and me-
ta-analyses. The titles and abstracts of the articles 
found in the different databases after applying 
the search equation were systematically analyzed 
by independent researchers. Then, the articles 
which met the inclusion criteria were reviewed 
completely and jointly by three researchers. Fina-
lly, the inclusion or exclusion of the studies was 
discussed.
2.2. Inclusion and exclusion criteria
Publications in languages other than English or Spa-
nish, and whose study population included chil-
dren (under 18 years of age) and pregnant women 
were excluded. Any symptomatology secondary to 
COVID-19 after at least two weeks following the 
acute stage was considered to be a persistent seque-
la. Studies with a sample size of less than 50 indivi-
duals were rejected.
2.3. Data extraction of the included articles
The references found on the systematic research 
were imported into the Zotero reference manager. 
After removing duplicate items, a single reference 
folder was created. The following information was 
chosen from the selected articles: number of sub-
jects studied, country where data were collected, 
mean age, sex, healthcare setting (inpatient, outpa-
tient, ICUs, healthcare staff) and mean follow-up 
time. The main objective of each study was poin-
ted out, as well as the enumeration of the seque-
lae observed. Symptomatology related exclusively 
to pain was also extracted. The prevalence of pain 
in different locations of the body was expressed in 
percentages, and their characteristics were listed.
3. Results
A total of 678 articles, retrieved as a result of the 
defined search equation, were reviewed based on 
their title and abstract. Subsequently, 54 publica-
tions were selected by independent researchers, 
who fully read all of them. Of them, 43 were exclu-
ded due to not meeting the inclusion criteria. The 
specific reasons for exclusion were the following: 
12 articles addressed chronic symptoms but did 
not include pain; 14 were single case reports or had 
sample sizes of less than 50; 4 were letters to the edi-
tor; 9 focused on acute or non-painful symptoms; 2 
did not meet age criteria; 1 did not meet language 
criteria; and 1 studied non-COVID population. A 
total of 11 studies were finally selected for analysis.
Most of the studies identified were published be-
tween July 2020 and January 2021: 4 were trans-
versal studies; 5 were cohort studies; 3 were retros-
pective; 2 were prospective; and 1 was a systematic 
review. The systematic review involved multi-cen-
ter studies. In the case of the other studies, 4 were 
carried out in the USA (one of them included 13 
North American states); the remaining ones in Italy, 
Spain, Switzerland, France, and Egypt.
Most of the studies were carried out by means of sur-
veys of patients recovered from acute SARS-CoV-2 
infection, on an outpatient basis and sometimes by 
phone due to the restrictions of home confinement 
during the pandemic. Of those publications, 5 fo-
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cused on patients that required hospitalization, 2 
on outpatients that experienced the acute phase of 
the disease, and 4 are not known to have required 
hospitalization. An average of 697 patients were in-
cluded in the selected studies. The mean age of the 
subjects was 45 years, with no differences regarding 
the sex of the patients studied.
Of all the included studies, headache is the most 
frequently reported painful sequela, with a repor-
ted prevalence of up to 44% after acute infection 
according to Sandra López-León et al. (4). Two ar-
ticles reported results on muscle pain (4, 18). Joint 
pain as a sequela after two weeks of infection was 
reported at 19% and 31% (4, 23). Post-COVID-19 
thoracic pain was reported in a percentage range of 
6% to 28% of patients included in the studies (20, 23, 
24, 25). Persistent sore throat was reported in 32% 
of patients, and non-specific or generalized pain 
was observed in up to 59% of cases, according to 
the study by Tenforde et al. (25). Neuropathic pain 
secondary to polyneuropathy in critically ill pa-
tients was significant among patients that required 
a prolonged ICU admission (15, 17). Figure 1 shows 
a visual scheme of the different painful sequelae.
In addition, SARS-CoV-2 has been reported to cau-
se damage to at the capillary microcirculation level, 
leading to tissue hypoxia and inflammation, and 
consequently to an increase in painful vascular-is-
chemic sequelae (6). It has also been reported that 
high levels of persistent antibodies after the infec-
tion are associated with fever, diarrhea and other 
sequelae (7).
4. Discussion
The COVID-19 pandemic is a revolution for health-
care as we know it. Firstly, because of the change it 
has caused in clinical care. Secondly, because of the 
pathophysiology of the disease, which remains lar-
gely unknown. Lastly, because of how it is affecting 
and will affect people’s health (8).
The COVID-19 pandemic has led many health ser-
vices to cease or reduce their activity. Treatments 
have been delayed or stopped (9, 10), resulting in 
negative effects such as increases in patients’ chro-
nic pain, disability and depression (13, 14, 39). The 
emergence of telemedicine as a barrier tool to curb 
the spread of the virus makes more necessary than 
ever engaging patients in their own health. Heal-
thcare professionals must pay close attention to 
properly educating patients on their underlying 
pathology and pain management options, while 
involving them in participatory decision-making 
processes. Telemedicine appears to be a promising 
resource in the management, treatment and fo-
llow-up of patients with chronic pain (10, 17, 39).
In addition, the painful sequelae of COVID-19 seem 
to respond to different etiopathogenic mechanisms. 
Reports range from headache, in mild forms of the 
disease, to painful inflammatory neuropathies in 
critically ill patients (32). Muscle pain is common 
in both mild and severe forms (33). The spectrum of 
ischemic pain has also emerged as a complication, 
linked to hypercoagulability and associated micro-
circulatory dysfunction (7). All of this is currently 
being researched in order to achieve a better un-
derstanding of the disease and the long-term symp-
toms it may cause.
Meanwhile, the contagiousness period for pa-
tients with a positive SARS-CoV-2 screening test is 
approximately twenty days (40). Once recovered 
from the acute symptoms, they are discharged from 
the hospital services where they have been treated 
(21). Many centers have already set up multidisci-
plinary units to follow up discharged patients after 
admission for COVID-19. However, there is also a 
large number of patients with post-COVID-19 pain 
who suffered a mild or moderate paucisymptoma-
tic acute infection, who are left out of these units 
because they were treated and followed up on an 
outpatient basis (4, 22, 25, 26, 27). Emphasis is pla-
ced on the quality of healthcare for those who, whi-
le “recovered” from the acute infection and out of 
danger, still suffer from symptoms that limit their 
quality of life (28). This study tried to shed light and 
prove that post-COVID-19 chronic pain is a reali-
ty which is sometimes underestimated and under-
treated. For that reason, the results of this analysis, 
supported by other studies, suggest the importance 
of setting up multidisciplinary units to care for the 
patients whose original condition was less severe. 
It is crucial that they receive long-term medical fo-
llow-up, aimed at detecting and treating symptoms 
derived from SARS-CoV-2 infection (3, 4, 5, 11, 25, 
36).
It is of great interest to evaluate in future studies the 
approach to post-COVID-19 pain according to loca-
tion, characteristics and response to the treatments 
carried out.
4.1. Limitations
The selection of articles by independent reviewers 
constituted a limitation, in terms of accuracy, du-
ring the literature research. This was expanded with 
literature taken from the references of the articles 
selected. The large databases consulted provided 
articles with little relation to COVID-19, in contrast 
to the new large library LitCovid, a database focu-
sed exclusively on SARS-CoV-2 (22). In addition, 
most of the selected articles did not address pain as 
the only sequela of COVID-19. There is still a lack 
of studies that provide larger sample sizes, as well 
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as prospective studies that address pain sequelae in 
their temporal dimension. The characteristics, in-
tensity, localization and other variables need to be 
examined in more depth to better classify pain as a 
sequela of COVID-19.
5. Conclusions
For many patients, COVID-19 infection does not 
end after acute infection recovery. At present, 
long-COVID phenomena are not well understood, 
let alone their potential consequences. Several lines 
of research aimed at shedding light on the natural 
history of a disease that is being experienced in real 
time. COVID-19 has painful sequelae of various 
typologies. There is already evidence of an increa-
se in the incidence of post-COVID-19 chronic pain. 
Further studies are required to identify the charac-
teristics of the different types of pain. The need to 
make appropriate use of telemedicine is emphasi-
zed. Moreover, multidisciplinary units that receive 
and study long-COVID cases are needed. This will 
allow a proper symptomatologic management and 
an optimization of the available resources to face 
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FIGURES
Figure 1. Most common post-COVID-19 painful sequelae.
Figure 2. Flowchart of the study selection in accordance with PRISMA (24).
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